Effects of duloxetine on motor and mood symptoms in Parkinson's disease: An open-label clinical experience.
Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan; Department of Neurophysiology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Electronic address: hnishijima-tky@umin.ac.jp.
Haruo
H
Nishijima
Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan; Department of Neurophysiology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Tatsuya
T
Ueno
Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan.
Tomoya
T
Kon
Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan.
Rie
R
Haga
Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan.
Yukihisa
Y
Funamizu
Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan.
Akira
A
Arai
Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan.
Chieko
C
Suzuki
Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan.
Jin-Ichi
JI
Nunomura
Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan.
Masayuki
M
Baba
Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan; Department of Neurophysiology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Masahiko
M
Tomiyama
D000339:Affect / Q000187:drug effects*; D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000068736:Duloxetine Hydrochloride / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology / Q000523:psychology; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D000068760:Serotonin and Noradrenaline Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D000068760:Serotonin and Noradrenaline Reuptake Inhibitors; D007980:Levodopa; D000068736:Duloxetine Hydrochloride
Duloxetine; Dyskinesia; Norepinephrine transporter; OFF time; Parkinson's disease; Serotonin transporter